Marinus Pharmaceuticals NASDAQ: MRNS is a micro-cap pharmaceutical stock with multiple Wall Street analysts seeing significant upside. Both Oppenheimer and Cantor Fitzgerald recently issued or reiterated massive price targets for the company. Oppenheimer's $6 target signals that shares could rise 241% from their current $1.76 level, which is over triple-bagger potential. Marinus Pharmaceuticals Today MRNS Marinus Pharmaceuticals $1.75 -0.01 (-0.57%) 52-Week Range $1.05 ▼ $11.26 Price Target $8.83 Add to Wat ...